---
title: A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer
  vaccination in patients with low-grade B cell lymphoma highlights challenges in
  translation from mouse to human studies
date: '2025-01-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39745391/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250102170914&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: Clinical results of T cell costimulatory receptor agonism
  have now repeatedly been inferior to the motivating preclinical results. Our study
  highlights potential barriers to clinical translation, particularly differences
  in preclinical and clinical reagents and the complex biology of these coreceptors
  in heterogenous T cell subpopulations, some of which may antagonize ...'
disable_comments: true
---
CONCLUSIONS: Clinical results of T cell costimulatory receptor agonism have now repeatedly been inferior to the motivating preclinical results. Our study highlights potential barriers to clinical translation, particularly differences in preclinical and clinical reagents and the complex biology of these coreceptors in heterogenous T cell subpopulations, some of which may antagonize ...